Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals (SNDX) granted inducement stock options for up to 175,000 shares of common stock to nineteen new employees on September 1, 2026, under its 2023 Inducement Plan.

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) granted inducement stock options for up to 175,000 shares of common stock to nineteen new employees on September 1, 2026, under its 2023 Inducement Plan.

The options vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.

News Explained

On September 1, 2026, Syndax granted options to purchase up to 175,000 shares to 19 new employees; the release describes a grant rather than an issuance, so any dilution is prospective: issuing the shares would increase total share count and reduce existing holders’ percentage ownership.

Argus Sep 8 session 1 alert

-3.02% close to close 1.6x rel. volume Open Argus

Details

News Market Reaction – SNDX

$1.86B Mkt Cap at Peak Alert

On Sep 8, the first trading day after this news, SNDX closed 3.02% below the previous close. Relative volume reached 1.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 8 session.

Key Figures

Shares covered: 175,000 shares New employees: 19 employees Vesting period: 4 years +3 more

Shares covered

175,000 shares

Inducement awards granted September 1, 2026

New employees

19 employees

Recipients of inducement awards

Vesting period

4 years

Stock option vesting schedule

Initial vesting

25%

Vests on the one-year anniversary

Monthly vesting

1/48th

Underlying shares vest monthly thereafter

Monthly vesting period

36 months

Period following the one-year anniversary

Historical Context

5 past events · Latest: Sep 01

5 events

1. Sep 01

   Investor conferences

   24h Move

   +4.2%

   Announced participation in two September investor conferences in New York

2. Aug 05

   Inducement grants

   24h Move

   -0.8%

   Granted inducement options covering 59,250 shares to five new employees

3. Aug 04

   Second-quarter earnings

   24h Move

   +4.4%

   Reported revenue growth and narrowed first-half net loss

4. Jul 28

   Earnings scheduling

   24h Move

   -4.3%

   Scheduled second-quarter results and conference call for August 4

5. Jul 14

   Pipeline update

   24h Move

   +5.4%

   Outlined new pipeline assets and multiple clinical development programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement awards, NASDAQ Listing Rule 5635(c)(4), menin inhibitor, monoclonal antibody, +1 more

5 terms

inducement awards financial

"the Company granted inducement awards to purchase up to 175,000 shares"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

NASDAQ Listing Rule 5635(c)(4) regulatory

"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

menin inhibitor medical

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

CSF-1 receptor medical

"antibody that blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grants did Syndax Pharmaceuticals (SNDX) announce on September 4, 2026?

Syndax Pharmaceuticals announced inducement awards of stock options to purchase up to 175,000 shares of common stock. These options were granted on September 1, 2026 to nineteen new employees under the company’s 2023 Inducement Plan.

How do the new Syndax (SNDX) inducement stock options vest?

The Syndax inducement stock options vest over four years. 25% of the shares vest on the one-year anniversary of the vesting commencement date, and the remaining 75% vest in 1/48th monthly installments over the next 36 months, subject to continued service.

Who received the new Syndax Pharmaceuticals (SNDX) inducement stock option grants?

The inducement stock option grants were awarded to nineteen new employees of Syndax Pharmaceuticals as part of their employment, under the company’s 2023 Inducement Plan.

Under which plan were the latest Syndax (SNDX) inducement stock options granted?

The newly announced inducement stock options were granted under Syndax Pharmaceuticals’ 2023 Inducement Plan, which is used to provide equity awards to new employees.